Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
13,080,549
-
Number of holders
-
159
-
Total 13F shares, excl. options
-
12,979,990
-
Shares change
-
-275,680
-
Total reported value, excl. options
-
$622,793,103
-
Value change
-
-$13,107,477
-
Put/Call ratio
-
0%
-
Number of buys
-
70
-
Number of sells
-
-88
-
Price
-
$47.98
Significant Holders of EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX) as of Q2 2020
183 filings reported holding EGRX - EAGLE PHARMACEUTICALS, INC. - Common Stock as of Q2 2020.
EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX) has 159 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12,979,990 shares
of 13,080,549 outstanding shares and own 99.23% of the company stock.
Largest 10 shareholders include BlackRock Inc. (1,729,319 shares), JANUS HENDERSON GROUP PLC (1,706,644 shares), Park West Asset Management LLC (1,120,235 shares), STATE STREET CORP (779,797 shares), VANGUARD GROUP INC (732,944 shares), Invesco Ltd. (476,153 shares), CREDIT SUISSE AG/ (418,092 shares), RENAISSANCE TECHNOLOGIES LLC (349,500 shares), DIMENSIONAL FUND ADVISORS LP (294,740 shares), and ARMISTICE CAPITAL, LLC (282,000 shares).
This table shows the top 159 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.